Tracers / [177Lu]Lu-PSMA-I&T

[177Lu]Lu-PSMA-I&T

Also written as [177Lu]Lu-PSMA-I&T
Radionuclide
Lu-177 t½ 9585 min
Modality
Therapy
Production route
Stage
Investigational / clinical (academic use)
Syntheses indexed
39

What it is

Compound class
Radiolabelled PSMA-targeting urea-based peptidomimetic (I&T = imaging-and-therapy ligand)
Target / mechanism
Prostate-specific membrane antigen (PSMA) PMID 26089548
Clinical application
PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer PMID 26089548
Theranostic pair
<a href="/tracers/ga68-psma-it/">ga68-psma-it</a>

Regulatory status

FDA
No FDA (Drugs@FDA/openFDA): no PSMA-I&T product found (distinct from the approved PSMA-617/vipivotide and PSMA-11/gozetotide products)
EMA (centralised)
No EMA medicines register export (2026-09-09): no 'PSMA-I&T' entry
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Modular-Lab EAZY
Eckert & Ziegler
vendor cassettenone96.3 ± 2.1 (synthesis no. 2-4)PSMA-I&T
piCHEM, Raaba-Grambach, Austria
37233924
2023 EJNMMI Radiopharm Chem
ModularLab EAZY (Eckert & Ziegler Eurotope GmbH, Berlin, Germany) — we increased the balanced radiochemical yield from 78 to 96.3% ± 2.1% (synthesis no. 2–4)
Elysia-Raytest
vendor cassettenone97.2 ± 2.4%
no
99.3 ± 0.6%PSMA-I&T ligand
ITM
42154134
2026 EJNMMI Radiopharm Chem
The [177Lu]Lu-PSMA I&T was produced using Elysia-Raytest's GAIA/LUNA synthesis modules. — a radiochemical yield of 97.2 ± 2.4% (without decay correction) was obtained
42474389
2026 Clin Nucl Med
Manual synthesisPSMA-I&T precursor
Scintomics, Fürstenfeldbruck, Germany
42274762
2026 Eur J Nucl Med Mol Imaging
radiolabeling was performed in-house
vendor cassettenone97.2 ± 2.4%
no
99.3 ± 0.6%PSMA I&T
ITM
42154134
2026 EJNMMI Radiopharm Chem
The [177Lu]Lu-PSMA I&T was produced using Elysia-Raytest's GAIA/LUNA synthesis modules. — a radiochemical yield of 97.2 ± 2.4% (without decay correction) was obtained
41927282
2026 J Nucl Med
Carrier-added [177Lu]Lutetium chloride
Isotopia Molecular Imaging Ltd
41680829
2026 J Exp Clin Cancer Res
Kit-based preparation41610875
2026 Nuklearmedizin
In-house preparations (using GMP-grade kits and in-house radiolabelling)
none>97%50%, 70%, 97%PSMA-I&T41474511
2025 EJNMMI Radiopharm Chem
41043997
2025 J Nucl Med
PSMA-I&T40998733
2025 J Nucl Med
iPHASE MultiSyn
iPHASE Technologies
vendor cassette99% ± 3%
no
94.3 ± 0.9% (0h HPLC)PSMA-I&T
Huayi
40696084
2025 EJNMMI Radiopharm Chem
This process was automated using an iPHASE MultiSyn radiochemistry module with sterile kits affording sterile and apyrogenic 177Lu-labeled radiopharmaceuticals in non-decay corrected yields > 95%. — a yield of 99% ± 3%.
Manual synthesismore than 95%PSMA-I&T
ABX
40147849
2025 J Nucl Med
Radiolabeling of the DOTA compounds was done at 85°C for 25 min, using ascorbic acid buffer and no-carrier-added [177Lu]LuCl3
39847077
2025 Eur J Nucl Med Mol Imaging
PSMA I&T
piCHEM, Raaba-Grambach, Austria
39225826
2024 Eur J Nucl Med Mol Imaging
38960712
2024 J Nucl Med
PSMA I&T (DOTAGA)38855174
2024 Theranostics
38724653
2024 Eur J Nucl Med Mol Imaging
DOTAGA-(I - y) fk-fk (Sub - KuE)38577331
2024 Front Oncol
Scintomics GRP / GRP-3V
Scintomics
vendor cassette>95%>95%PSMA-I&T38378689
2024 Breast Cancer Res
a cassette synthesizer type GRP 3 V (Scintomics, Germany) was used — Radiochemical purities and yields were > 95% (measured with radio-HPLC).
38069337
2023 Int J Mol Sci
Modular-Lab PharmTracer
Eckert & Ziegler
vendor cassette>95%PSMAI&T
Scintomics, Fürstenfeldbruck, Germany
38067427
2023 Molecules
Radiosyntheses were performed on a Modular-Lab PharmTracer (Eckert & Ziegler GmbH, Berlin, Germany) using the corresponding single-use disposable cassettes.
37853247
2023 EJNMMI Phys
Modular-Lab EAZY
Eckert & Ziegler
vendor cassettenone96.3 ± 2.1PSMA-I&T
piCHEM, Raaba-Grambach, Austria
37233924
2023 EJNMMI Radiopharm Chem
All three radiopharmaceuticals were successfully synthesized in high radiochemical purities and yields on the ML Eazy. — we increased the balanced radiochemical yield from 78 to 96.3% ± 2.1% (synthesis no. 2–4)
Modular-Lab PharmTracer
Eckert & Ziegler
vendor cassetteSPE96.9 ± 0.5%PSMA I&T
piCHEM, Raaba-Grambach, Austria
36971890
2023 EJNMMI Radiopharm Chem
[177Lu]Lu-PSMA I&T was prepared using an automated cassette based synthesis module (PharmTracer, Modular Lab, Eckert&Ziegler, Berlin, Germany)
36629878
2023 Eur J Nucl Med Mol Imaging
Scintomics GRP / GRP-3V
Scintomics
vendor cassettenonePSMA-I&T
ABX
36166155
2022 EJNMMI Radiopharm Chem
[177Lu]Lu-PSMA-I&T and [177Lu]Lu-PSMA-617 was produced with a Scintomics GRP module
Manual synthesis96.8 ± 0.9%<95% in 24 hPSMA-I&T
ABX
35807385
2022 Molecules
For the radiolabeling of [177Lu]Lu-PSMA-I&T, a manual synthesis was used. — A typical synthesis time for the complexation reaction yielding [177Lu]Lu-PSMA I&T in 60 min with a radiochemical yield of 96.8 ± 0.9% (n = 5).
35650263
2022 Eur J Nucl Med Mol Imaging
Manual synthesis>95%PSMA I&T precursor35086894
2022 J Nucl Med
177Lu labeling of PSMA ligands according to standard manual procedures resulted in a radiochemical purity of more than 95%
34887335
2022 J Nucl Med
33840558
2021 Eur Urol
PSMA-I&T33778927
2021 Curr Oncol Rep
Manual synthesis>95%>90%PSMA-I&T
Prof. Dr. Hans-Jürgen Wester, Technische Universität München
33094433
2021 Eur J Nucl Med Mol Imaging
Labeling of PSMA-617, PSMA-I&T, and JVZ-007 was performed as previously described — For all labelings, the radiochemical yield was > 95% and the radiochemical purity was > 90%.
PSMA-I&T32374450
2020 J Labelled Comp Radiopharm
using the same synthesis module
98%PSMA-I&T40425733
2026 Nat Protoc
PSMA I&T26089548
2015 J Nucl Med
42696922
2026 Appl Radiat Isot
42324414
2026 Mol Imaging Biol

Precursor

Common precursor
PSMA-I&T PMID 37233924 (DOI 10.1186/s41181-023-00196-1)
Suppliers seen in the literature
piCHEM (Raaba-Grambach, Austria)
Cited suppliers in indexed syntheses
ABX, Huayi, ITM, Isotopia Molecular Imaging Ltd, Prof. Dr. Hans-Jürgen Wester, Scintomics, Fürstenfeldbruck, piCHEM
Typical final purification
none (direct sterile filtration, no chromatographic step)

Need this precursor?We can point you to suppliers for [177Lu]Lu-PSMA-I&amp;T, or handle the enquiry for you.

Get in touch

Quality control Derived from the published synthesis

Ph. Eur. monograph
USP monograph
AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityOsmolalityMolar activityMetal impuritiesLu-177m
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Lu-177 preparation -> Lu-177m content (rule); therapeutic radiopharmaceutical -> osmolality (rule); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [177Lu]Lu-PSMA-I&amp;T.

Get in touch

Notes

Added from reverse module search (stage 6); 10 article(s) with Lu-177.